Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
0 hedge funds and large institutions have $0 invested in Timber Pharmaceuticals, Inc. in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 11 closing their positions.
100% less funds holding
Funds holding: 11 → 0 (-11)
100% less capital invested
Capital invested by funds: $1.63M → $0 (-$1.63M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 11
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$747K |
| 2 |
PCM
PenderFund Capital Management
Vancouver,
British Columbia, Canada
|
-$391K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$134K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$115K |
| 5 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$78.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Tudor Investment Corp
Stamford,
Connecticut
| – | -$747K | -251,037 | Closed |
|
|
PCM
2
PenderFund Capital Management
Vancouver,
British Columbia, Canada
| – | -$391K | -96,790 | Closed |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$134K | -45,105 | Closed |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| – | -$115K | -38,687 | Closed |
|
|
YCM
5
Yakira Capital Management
Westport,
Connecticut
| – | -$78.4K | -26,366 | Closed |
|
6
Geode Capital Management
Boston,
Massachusetts
| – | -$66.3K | -22,292 | Closed |
|
7
Citadel Advisors
Miami,
Florida
| – | -$48.4K | -16,260 | Closed |
|
8
State Street
Boston,
Massachusetts
| – | -$43K | -14,442 | Closed |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$5.35K | -1,797 | Closed |
|
10
UBS Group
Zurich,
Switzerland
| – | -$4.94K | -1,659 | Closed |
|
11
Wells Fargo
San Francisco,
California
| – | -$65 | -22 | Closed |
|
TMBR Hedge Fund Activity: Q4 2023 in Review
0 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q4 2023, worth a combined $0 — down 100% from $1.63M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TMBR and 0 opened new positions — a net loss of 11 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Tudor Investment Corp, exiting entirely with an estimated $747K sold.
- 0 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q4 2023, down from 11 in Q3 2023.
- Funds reported $0 of Timber Pharmaceuticals, Inc. stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new Timber Pharmaceuticals, Inc. positions in Q4 2023 and 11 closed out, a net change of -11 holders.
- The largest Timber Pharmaceuticals, Inc. seller in Q4 2023 was Tudor Investment Corp, an estimated $747K sold.
Based on aggregated 13F filings for Q4 2023.